Advances in hematology: The reemergence of aspirin for the prevention of venous thromboembolism

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 2, 2012, Pages 120-121

  Eikelboom, John ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PLACEBO;

ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; LUNG EMBOLISM; RISK FACTOR; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; HUMAN; THROMBOEMBOLISM;

ANTICOAGULANTS; ASPIRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84857077438     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-1302.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
3. Antithrombotic Trialists' Combination. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
4. Karthikeyan G, Eikelboom JW, Turpie AG, Hirsh J. Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol. 2009;146:142-149.
5. Becattini C, Agnelli G, Poggio R, et al. Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked venous thromboembolism. The Warfasa Study. Blood (ASH Annual Meeting Abstracts). 2011;118; Abstract 543.